Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, TriSalus Life Sciences, Inc. reported revenue of $45M, up 53.4% year over year. Operating margin was -59.7% and net margin -86.9%, on a free-cash-flow margin of -41.9% with capital expenditure at 2.0% of revenue. Every figure is computed directly from TLSI's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $45M | -59.7% | -86.9% |
| FY2024 | $29M | -122.9% | -102.1% |
| FY2023 | $19M | -294.3% | -320.7% |
| FY2022 | $12M | -293.9% | -380.6% |
| FY2021 | n/a | n/a | n/a |
How does TLSI compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: A · ACHR · AEHR · AERG · AEVA · AIRI
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.